<DOC>
	<DOCNO>NCT01443351</DOCNO>
	<brief_summary>Thrombopoietin Receptor Agonists ( TPO-ra ) novel treatment modality patient refractory Primary Immune Thrombocytopenia ( ITP ) , data available long-term effect drug . In observational study , effect adverse effect include evaluation bone marrow biopsy do fix interval record ITP patient treat TPO-ra . For patient , blood sample collect research use .</brief_summary>
	<brief_title>Long-term Safety Study Treatment With Thrombopoietin Agonists Eltrombopag Romiplostim Patients With Immune Thrombocytopenia ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Adult patient ITP platelet count &lt; 25 x10*9/L &lt; 50 x10*9/L bleeding symptom meet criteria treatment TPOra Females must use contraceptive applicable least three month inclusion Pregnancy nursing Former thromboembolic event exclude one incidence deep venous thrombosis complication surgery pregnancy one incidence cerebral embolism complication atrial fibrillation Liver insufficiency ( eltrombopag ) TPOra contraindication ( e.g . allergy ) TPOra treatments less 6 month prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>ITP</keyword>
	<keyword>romiplostim</keyword>
	<keyword>eltrombopag</keyword>
	<keyword>bone marrow fibrosis</keyword>
	<keyword>long-term safety</keyword>
</DOC>